# Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)

> **NCT00908921** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 391 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** GLIMEPIRIDE

## Key facts

- **NCT ID:** NCT00908921
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 391 (ACTUAL)
- **Last updated:** 2012-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00908921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00908921, "Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00908921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*